TrialBritish journal of cancer2019

PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study.

Mark D Pegram et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.